Rapport Therapeutics (RAPP) Competitors $20.84 +1.83 (+9.63%) (As of 09/18/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RAPP vs. XENE, DYN, MRUS, BHC, IOVA, KYMR, MOR, MORF, HCM, and TWSTShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Xenon Pharmaceuticals (XENE), Dyne Therapeutics (DYN), Merus (MRUS), Bausch Health Companies (BHC), Iovance Biotherapeutics (IOVA), Kymera Therapeutics (KYMR), MorphoSys (MOR), Morphic (MORF), HUTCHMED (HCM), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Xenon Pharmaceuticals Dyne Therapeutics Merus Bausch Health Companies Iovance Biotherapeutics Kymera Therapeutics MorphoSys Morphic HUTCHMED Twist Bioscience Xenon Pharmaceuticals (NASDAQ:XENE) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings. Do analysts recommend XENE or RAPP? Xenon Pharmaceuticals currently has a consensus target price of $58.78, suggesting a potential upside of 45.53%. Rapport Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 64.40%. Given Rapport Therapeutics' higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Xenon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in XENE or RAPP? 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 5.5% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in XENE or RAPP? Xenon Pharmaceuticals received 412 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Rapport Therapeutics an outperform vote while only 69.70% of users gave Xenon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformXenon PharmaceuticalsOutperform Votes41469.70% Underperform Votes18030.30% Rapport TherapeuticsOutperform Votes2100.00% Underperform VotesNo Votes Does the media prefer XENE or RAPP? In the previous week, Rapport Therapeutics had 3 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 8 mentions for Rapport Therapeutics and 5 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.38 beat Rapport Therapeutics' score of 1.18 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is XENE or RAPP more profitable? Rapport Therapeutics' return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -24.16% -23.15% Rapport Therapeutics N/A N/A N/A Which has better valuation & earnings, XENE or RAPP? Rapport Therapeutics has lower revenue, but higher earnings than Xenon Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$9.43M323.77-$182.39M-$2.71-14.87Rapport TherapeuticsN/AN/AN/AN/AN/A SummaryXenon Pharmaceuticals beats Rapport Therapeutics on 8 of the 13 factors compared between the two stocks. Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport Therapeutics IndustryMedical SectorNASDAQ ExchangeMarket Cap$768.18M$2.14B$5.68B$8.27BDividend YieldN/A15.06%4.34%4.08%P/E RatioN/A10.64143.7418.58Price / SalesN/A146.501,618.6173.18Price / CashN/A91.4137.1831.90Price / BookN/A1.334.854.56Net IncomeN/A$84.40M$115.00M$223.87M7 Day Performance11.05%2.94%4.41%5.73%1 Month Performance0.91%1.70%9.61%9.09%1 Year PerformanceN/A15.11%29.39%12.63% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XENEXenon Pharmaceuticals3.3917 of 5 stars3.39 / 5 stars$40.30+0.5%$58.78+45.9%+8.8%$3.05B$9.43M-14.87210Positive NewsDYNDyne Therapeutics4.0407 of 5 stars4.04 / 5 stars$34.65+0.1%$51.40+48.3%+273.7%$3.03BN/A-8.73100Analyst DowngradeShort Interest ↓MRUSMerus3.5578 of 5 stars3.56 / 5 stars$49.60-1.0%$80.20+61.7%+105.6%$2.91B$35.19M-17.9137News CoverageBHCBausch Health Companies3.855 of 5 stars3.86 / 5 stars$8.04+12.0%$7.33-8.8%-15.7%$2.90B$9.20B-6.4820,270Analyst DowngradeOptions VolumeNews CoverageGap UpHigh Trading VolumeIOVAIovance Biotherapeutics4.1823 of 5 stars4.18 / 5 stars$10.35-0.7%$23.00+122.2%+97.7%$2.90B$32.77M-5.75500KYMRKymera Therapeutics1.197 of 5 stars1.20 / 5 stars$46.91-0.8%$48.67+3.7%+148.3%$2.88B$88.55M-18.69170Insider SellingPositive NewsMORMorphoSys0.1329 of 5 stars0.13 / 5 stars$18.96flat$11.78-37.9%N/A$2.86B$238.28M-5.45730News CoverageMORFMorphic1.3334 of 5 stars1.33 / 5 stars$56.99flat$54.25-4.8%+7.1%$2.85B$520,000.00-16.28100HCMHUTCHMED2.031 of 5 stars2.03 / 5 stars$16.34+0.2%$20.55+25.8%+10.8%$2.85B$420.26M0.001,988Positive NewsTWSTTwist Bioscience2.0784 of 5 stars2.08 / 5 stars$47.38-0.6%$48.22+1.8%+127.5%$2.76B$295.21M-14.10990Gap Up Related Companies and Tools Related Companies: XENE Competitors DYN Competitors MRUS Competitors BHC Competitors IOVA Competitors KYMR Competitors MOR Competitors MORF Competitors HCM Competitors TWST Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RAPP) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredCrypto ‘Banana Zone’ Incoming…What if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
